BAUS, EAU and NICE have suggested that hospitals switch to our EMDA®+Mitomycin-C treatment due to the worldwide shortage of BCG.
EMDA®+Mitomycin-C (MMC) has been proven to significantly prolong the disease-free interval of non-muscle invasive bladder cancer (NMIBC) patients. This treatment is pre-TURBT and has also been shown to reduce the risk of recurrence in high and intermediate-risk NMIBC patients.
In addition, the EMDA®+MMC treatment has been indicated for patients refractory to or unable to tolerate BCG treatment, it is well-tolerated and safe with no systemic effects or toxicity.
Our team are on Stand 445 at BAUS 2019 in Glasgow from Monday 24 June to Wednesday 26 June. If you are attending, please drop by to find out more about the advantages of the EMDA®+MMC treatment for your clinic.
If you prefer, you can book a meeting directly with Robin Luper on +44 (0)7774-930316 or send us an email to email@example.com and we’ll get in touch with further information and prices.
4 Transurethral Resection of a Bladder Tumour